Abstract
Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both BRAF wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.
| Original language | English |
|---|---|
| Article number | 208 |
| Pages (from-to) | 1-15 |
| Number of pages | 15 |
| Journal | Life |
| Volume | 10 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2020 Sept |
Keywords
- BRAF inhibitors
- Combination therapy
- Immune checkpoints inhibitors
- MEK inhibitors
- Metastatic melanoma
ASJC Scopus subject areas
- Ecology, Evolution, Behavior and Systematics
- Biochemistry, Genetics and Molecular Biology(all)
- Space and Planetary Science
- Palaeontology